This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
A published deterministic state-transition decision model was used (and updated) to simulate the natural history of HCV infection in patients co-infected with HIV. An extensive description of health states and transition patterns was provided. A simplified schematic of the model was reported. The cycle length was 1 month and a lifetime horizon was considered. The analysis assumed 48 weeks of HCV therapy for all patients.
Sources searched to identify primary studies
The clinical data came from several sources, although only some of these were described in detail. Treatment effectiveness came from a clinical trial (APRICOT) that involved 868 individuals in 19 countries. Excess mortality due to HIV came from the Multicenter AIDS Cohort Study. Little information on the other primary studies was provided.
Methods used to judge relevance and validity, and for extracting data
It was unclear whether a systematic review of the literature was undertaken to identify the primary studies. However, the authors chose the most recent clinical trial (APRICOT) to obtain clinical effectiveness with the different treatments analysed, which this should have ensured high internal and external validity (multi-country). Some assumptions based on published data were also made.
Measure of benefits used in the economic analysis
The summary benefit measure used was the life-years (LYs). These were estimated using the decision model. The benefits were discounted at an annual rate of 3%.
Direct costs
The analysis of the costs included only direct medical costs, despite the fact that the authors stated that a societal perspective had been adopted. The analysis included the costs of drugs and annual HCV/HIV care (compensated cirrhosis, ascites, variceal haemorrhage, hepatic encephalopathy, hepatocellular carcinoma and liver transplant). The cost categories included hospitalisations, outpatient visits, laboratory tests, medications and interventions. A detailed breakdown of the cost items was not given, but the costs were presented as macro-categories. The unit costs and the quantities of resources used were not presented separately. The costs and quantities of resources used were derived from average wholesale prices for drugs and from published studies for the other items. Discounting was relevant, as the long-term costs were evaluated, and an annual rate of 3% was used. The price year was 2004.
In the sub-group of men with genotype I, the expected LYs were 11.63 with no treatment, 11.71 with IFN-RIB, 11.83 with pegIFN and 12.06 with pegIFN-RIB.
In the sub-group of men with non-genotype I, the expected LYs were 11.63 with no treatment, 11.88 with IFN-RIB, 12.09 with pegIFN and 12.52 with pegIFN-RIB.
In the sub-group of women with genotype I, the expected LYs were 12.28 with no treatment, 12.37 with IFN-RIB, 12.48 with pegIFN and 12.73 with pegIFN-RIB.
In the sub-group of women with non-genotype I, the expected LYs were 12.28 with no treatment, 12.55 with IFN-RIB, 12.76 with pegIFN and 13.20 with pegIFN-RIB.
Cost results
In the sub-group of men with genotype I, the expected costs were $240,300 with no treatment, $256,400 with IFN-RIB, $261,100 with pegIFN and $271,700 with pegIFN-RIB.
In the sub-group of men with non-genotype I, the expected costs were $240,300 with no treatment, $257,900 with IFN-RIB, $263,400 with pegIFN and $275,600 with pegIFN-RIB.
In the sub-group of women with genotype I, the expected costs were $252,200 with no treatment, $268,400 with IFN-RIB, $273,200 with pegIFN and $284,000 with pegIFN-RIB.
In the sub-group of women with non-genotype I, the expected costs were $252,200 with no treatment, $270,000 with IFN-RIB, $275,700 with pegIFN and $288,400 with pegIFN-RIB.
Synthesis of costs and benefits
Incremental cost-effectiveness ratios (i.e. the incremental cost per LY gained) were calculated in order to combine the costs and benefits.
Regardless of genotype and gender, combination therapy with pegIFN-RIB was the most effective option, whilst IFN-RIB and pegIFN alone were extended dominated strategies.
The incremental cost per LY gained for pegIFN-RIB compared with no treatment was $73,000 in men with genotype 1, $39,700 in men with non-genotype 1, $70,700 in women with genotype 1 and $39,300 in women with non-genotype 1.
Similar results were achieved in an exploratory analysis in which it was assumed that treatment was ceased when no early virological response occurred.
The sensitivity analysis showed that the results were insensitive to varying parameters across plausible ranges. The costeffectiveness ratios were slightly sensitive to variations in the annual excess death rate due to HIV, fibrosis progression rates, and treatment efficacies in non-cirrhotic patients.
In a two-way sensitivity analysis, when treatment effectiveness exceeded 50%, the cost-effectiveness ratios were consistently less than $50,000, regardless of the relative risk of fibrosis progression. When treatment effectiveness exceeded 50%, the cost-effectiveness ratio was always lower than $100,000.
The discount rate strongly affected the conclusions of the analysis. With no discounting, the incremental costeffectiveness ratio was approximately 60% lower than in the base-case analysis. With a 5% discount rate, the ratio was about 140% higher than in the base-case.
